MYC and plasma cell myeloma: Indeed, in the current study, we validated the time-dependent reduction of c-Myc as well as an increase of c-MycK323ac in myeloma cell lines on treatment with class I/II and class I HDACi, compared with those treated with control IgG1 at protein levels (Fig. 5C), but not in human normal MNCs, highlighting that c-Myc modification by HDACi is tumor-selective and may correlate with cytotoxic response in myeloma cells.